Orexigen targets growing obesity problem in Spain

25 January 2017
2019_biotech_test_vial_discovery_big

American biotech Orexigen Therapeutics (Nasdaq: OREX) will collaborate with Spanish pharmaceutical firm Laboratorios Farmacéuticos Rovi (MCE: ROVI) to commercialize and distribute Mysimba in Spain.

Mysimba (naltrexone HCl/bupropion HCl prolonged release) is approved by the European Medicines Agency for the management of weight in adult patients in the presence of one or more weight-related co-morbidities.

More than half of the population in Spain is either obese or overweight.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology